Search

Your search keyword '"Poizeau F"' showing total 169 results
Start Over Author "Poizeau F"
169 results on '"Poizeau F"'

1. Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm

Author

Poizeau, F., Leducq, S., Fardet, L., Beylot-Barry, M., Chaby, Guillaume, Chastagner, M., Corgibet, F., Gouillon, L., Jouan, N., Jullien, D., Acher, A., Amatore, F., Amici, J.-M., Aubert, H., Aubin, F., Beneton, N., Bouilly, D, Bursztejn, A.-C., Buzenet, C., Chamaillard-Pujol, M., Charles, J., Cottencin-Charriere, A.-C., Duval Modeste, B., Fauconneau, A., Fougerousse, A.-C., Girard, C., Goujon, C., Khemis, A., Le Ru, Y., Lepelley-Dupont, C., Mahé, E., Marcellin, X., Nicolas, C., Pallure, V., Parier, J., Quiles, N., Stoebner, P.-E., Tauber, M., Vermersch, A., Viguier, M., Villani, A.P., Chosidow, O., and Guillot, B.

Published
2024
Full Text
View/download PDF

2. Isotretinoin: Past, present and future. A French perspective

Author

Leducq, S., Poizeau, F., Chaby, G., Tannous, J., Ballanger-Desolneux, F., Baubion, E., Bertolotti, A., Cogrel, O., Droitcourt, C., Garnier, V., Gautier, S., Hefez, L., Hotz, C., Jonville-Béra, A.-P., Jouan, N., Mahé, A., Mahé, E., Martinho, G., Micallef, J., Puszkarek, T., Dupin, N., Ly, S., Beylot-Barry, M., Corgibet, F., Guillot, B., and Chosidow, O.

Published
2024
Full Text
View/download PDF

3. Promoting clinical research in community-based practice: Threats and opportunities

Author

Poizeau, F., Maruani, A., Staumont-Sallé, D., Jouan, N., Ly, S., Schollhammer, M., Reverte, M., Dibao-Dina, C., Duong, T.-A., Matard, B., Penso-Assathiany, D., Dupuy, A., Carriot, M., Seï, J.-F., Corgibet, F., Guillot, B., Barbarot, S., Leducq, S., Bertolotti, A., Tannous, J., Chaby, G., Jullien, D., Pépin, E., Quéreux, G., Beylot-Barry, M., and Chosidow, O.

Published
2024
Full Text
View/download PDF

4. Promouvoir la recherche clinique en dermatologie libérale : freins et opportunités

Author

Poizeau, F., Maruani, A., Staumont-Sallé, D., Jouan, N., Ly, S., Schollhammer, M., Reverte, M., Dibao-Dina, C., Duong, T.-A., Matard, B., Penso-Assathiany, D., Dupuy, A., Carriot, M., Seï, J.-F., Corgibet, F., Guillot, B., Barbarot, S., Leducq, S., Bertolotti, A., Tannous, J., Chaby, G., Jullien, D., Pépin, E., Quéreux, G., Beylot-Barry, M., and Chosidow, O.

Published
2024
Full Text
View/download PDF

5. Isotrétinoïne : quelles actualités en dermatologie ? Conclusions du séminaire Centre de preuves en dermatologie et groupe DEFI de la SFD

Author

Leducq, S., Poizeau, F., Chaby, G., Tannous, J., Ballanger-Desolneux, F., Baubion, E., Bertolotti, A., Cogrel, O., Droitcourt, C., Garnier, V., Gautier, S., Hefez, L., Hotz, C., Jonville-Béra, A.-P., Jouan, N., Mahé, A., Mahé, E., Martinho, G., Micallef, J., Puszkarek, T., Dupin, N., Ly, S., Beylot-Barry, M., Corgibet, F., Guillot, B., and Chosidow, O.

Published
2024
Full Text
View/download PDF

15. Utilisation concomitante d’inhibiteurs de la pompe à protons et de thérapie ciblée : impact sur la durée de traitement par thérapie ciblée et la survie des patients atteints de mélanome métastatique

Author

Poizeau, F., primary, Frédéric, B., additional, Lemaitre, F., additional, Tron, C., additional, Pracht, M., additional, Russo, D., additional, Dinulescu, M., additional, Lesimple, T., additional, Oger, E., additional, and Dupuy, A., additional

Published
2022
Full Text
View/download PDF

16. Utilisation des traitements systémiques pour la prise en charge du psoriasis modéré à sévère : consensus d’experts par méthode DELPHI

Author

Poizeau, F., primary, Leducq, S., additional, Guillot, B., additional, Beylot-Barry, M., additional, Chaby, G., additional, Chastagner, M., additional, Corgibet, F., additional, Gouillon, L., additional, Jullien, D., additional, Acher, A., additional, Amatore, F., additional, Amici, J.M., additional, Aubert, H., additional, Aubin, F., additional, Beneton, N., additional, Bouilly, D., additional, Bursztejn, A.C., additional, Buzenet, C., additional, Chamaillard-Pujol, M., additional, Charles, J., additional, Cottencin-Charriere, A.C., additional, Duval, M.B., additional, Fauconneau, A., additional, Fougerousse, A.C., additional, Girard, C., additional, Goujon, C., additional, Khemis, A., additional, Le Ru, Y., additional, Lepelley-Dupont, C., additional, Mahé, E., additional, Marcellin, X., additional, Nicolas, C., additional, Pallure, V., additional, Parier, J., additional, Paul, C., additional, Quiles, N., additional, Richard, M.A., additional, Stoebner, P.E., additional, Tauber, M., additional, Vermersch, A., additional, Viguier, M., additional, Villani, A., additional, Chosidow, O., additional, and Fardet, L., additional

Published
2022
Full Text
View/download PDF

20. Association of psychiatric history with delay in the isotretinoin introduction among patients with severe acne. A French population-cohort study

Author

Laurent, C, Balusson, F, Droitcourt, C, Poizeau, F, Travers, D, Oger, E, Dupuy, A, Dupuy, Alain, Chard-Hutchinson, Xavier, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], This work was supported by a grant from the French Society of Dermatology (SFD, and Société Française de Dermatologie).

Subjects
[SDV] Life Sciences [q-bio], Infectious Diseases, [SDV]Life Sciences [q-bio], Dermatology, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; No abstract available

Published
2022

27. Durées de traitement et post-traitement des traitements systémiques dans une cohorte nationale française d’enfants ayant une dermatite atopique

Author

Chambrelan, E., primary, Barbarot, S., additional, Bekel, L., additional, Poizeau, F., additional, Mahé, E., additional, Puzenat, E., additional, Delaunay, J., additional, Mallet, S., additional, Bessis, D., additional, Maruani, A., additional, Miquel, J., additional, Raison-Peyron, N., additional, Darrieux, L., additional, Abasq, C., additional, Phan, A., additional, Aurélie, D.-T., additional, Kupfer, I., additional, Bonniaud, B., additional, Bouzille, G., additional, Law Ping Man, S., additional, Dupuy, A., additional, and Droitcourt, C., additional

Published
2020
Full Text
View/download PDF

31. Mycoplasma genitaliumscreening in a specialized French unit: A retrospective study

Author

Herms, F., Poizeau, F., Anyfantakis, V., Bonhomme, P., Chaine-Sidibé, B., Louison, J.-B., Berçot, B., Bagot, M., and Fouéré, S.

Abstract

Mycoplasma genitalium(MG) infection accounts for 10–35% of non-gonococcal non-chlamydial (NGNC) urethritis. However, given that most people infected with MG do not develop symptoms and that antimicrobial resistance is increasing worldwide, there is no evidence of any benefits of screening asymptomatic individuals. We conducted this study to describe MG screening practices and outcomes at a French Sexually Transmitted Infections (STI) center in which MG testing was performed selectively and multiplex assays were not carried out [i.e., simultaneous screening for Chlamydia trachomatis(CT), Neisseria gonorrhoeae(NG), and MG].

Published
2022
Full Text
View/download PDF

34. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma

Author

Manson, G., primary, Brice, P., additional, Herbaux, C., additional, Silva, M. G., additional, Bouabdallah, K., additional, Deau, B., additional, Bouteloup, J., additional, Schiano, J. M., additional, Nicolas-Virelizier, E., additional, Maerevoet, M., additional, Ghesquieres, H., additional, Stamatoullas, A., additional, Antier, C., additional, Carlo-Stella, C., additional, de Charette, M., additional, Poizeau, F., additional, Dercle, L., additional, and Houot, Roch, additional

Published
2020
Full Text
View/download PDF

36. Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study

Author

Briand, C, primary, Gourier, G, additional, Poizeau, F, additional, Jelti, L, additional, Bachelerie, M, additional, Quéreux, G, additional, Jeudy, G, additional, Acquitter, M, additional, Ingen-Housz-Oro, S, additional, Caux, F, additional, Prost, C, additional, Darrigade, A, additional, Heron Mermin, D, additional, Mahé, E, additional, Picart Dahan, C, additional, Richard, M, additional, Clerc, C, additional, Salle de Chou, C, additional, Plée, J, additional, Abasq-Thomas, C, additional, Misery, L, additional, and Brenaut, E, additional

Published
2020
Full Text
View/download PDF

38. Caractéristiques du prurit dans la pemphigoïde bulleuse et impact sur la qualité de vie: l’étude prospective multicentrique PruriPB

Author

Briand, C., primary, Gourier, G., additional, Poizeau, F., additional, Jelti, L., additional, Bachelerie, M., additional, Quéreux, G., additional, Jeudy, G., additional, Acquitter, M., additional, Oro, S., additional, Caux, F., additional, Darrigade, A.S., additional, Heron Mermin, D., additional, Mahé, E., additional, Picart Dahan, C., additional, Richard, M.-A., additional, Clerc, C.J., additional, Salle De Chou, C., additional, Bernard, P., additional, Abasq, C., additional, Misery, L., additional, and Brenaut, E., additional

Published
2019
Full Text
View/download PDF

39. Isotrétinoïne et facteurs de risque de tentative de suicide : série de cas et étude cas témoin à partir des données médico-administratives françaises du Système National des Données de Santé (SNDS), entre 2010 et 2014

Author

Droitcourt, C., primary, Poizeau, F., additional, Kerbrat, S., additional, Balusson, F., additional, Drezen, E., additional, Happe, A., additional, Travers, D., additional, Oger, E., additional, and Dupuy, A., additional

Published
2019
Full Text
View/download PDF

40. Early major adverse cardiovascular events following the initiation of the anti-interleukin 12/23 antibody ustekinumab. A population-based case-time-control study

Author

Poizeau, F., Nowak, E., Kerbrat, S., Droitcourt, C., Sbidian, E., Guillot, B., Bachelez, H., Ait-Oufella, H., Oger, E., Dupuy, A., Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Lapeyronie [Montpellier] (CHU), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], Monoclonal antibody, Major adverse cardiovascular events (MACE), [SDV]Life Sciences [q-bio], Ustekinumab, cardiovascular diseases, Cardiovascular risk
Abstract

International audience; Ustekinumab, a monoclonal antibody that targets interleukin (IL)-12/23, is used to treat psoriasis, psoriatic arthritis and Crohn disease. In 2011, a meta-analysis of randomized trials alerted on a potential risk of major adverse cardiovascular events (MACE) within the first months after the initiation of anti-IL-12/23 antibodies. Our objective was to assess if ustekinumab initiation may trigger MACE. Using the French National Health Insurance database, covering 66 million subjects, we included all patients exposed to ustekinumab between 2010 and 2016, classified according to their cardiovascular risk level (high vs. low risk). We conducted a case-time-control study. We defined the ‘risk’ period as the 6 months before MACE, defined as myocardial infarctions and strokes, and the ‘reference’ period as the 6 months before the risk period. The initiation of ustekinumab was screened in both periods, enabling to assess the odds-ratio (OR) between the initiation of ustekinumab and MACE. Among the 9290 patients exposed to ustekinumab, 179 displayed MACE: 65 myocardial infarctions, 68 unstable anginas and 46 strokes. Among patients at high-level cardiovascular risk, a significant association between ustekinumab initiation and MACE occurrence was identified (OR, 4.17; 95% CI, 1.19-14.59). Conversely, no association was found in patients at low-level cardiovascular risk (OR, 0.30; 95% CI, 0.03-3.13). From real-world data, we suggest that ustekinumab initiation could trigger MACE in patients at high cardiovascular risk, in line with current immunologic models of atherosclerotic disease. These results should call for caution regarding the prescription of ustekinumab in patients at high cardiovascular risk.

Published
2019

47. Transformation de la prise en charge et de la survie des patients atteints de mélanome métastatique : analyse en « vie réelle » à l’échelle nationale (SNDS-SNIIRAM 2010–2016)

Author

Poizeau, F., primary, Kerbrat, S., additional, Happe, A., additional, Rault, C., additional, Drezen, E., additional, Tuppin, P., additional, Guillot, B., additional, Thuret, A., additional, Boussemart, L., additional, Dinulescu, M., additional, Pracht, M., additional, Lesimple, T., additional, Oger, E., additional, and Dupuy, A., additional

Published
2018
Full Text
View/download PDF

49. Major Role for TRPV1 and InsP3R in PAR2-Elicited Inflammatory Mediator Production in Differentiated Human Keratinocytes

Author

Misery, Laurent, Brenaut, Emilie, Pierre, Ophélie, Le Garrec, Raphaele, Gouin, Olivier, Lebonvallet, Nicolas, Abasq‐Thomas, Claire, Talagas, Matthieu, Le Gall‐Ianotto, Christelle, Besner‐Morin, Catherine, Fluhr, Joachim, Leven, Cyril, Chéret, Jérémy, Ponce, Leslie, Bertolini, Marta, Paus, Ralf, L’Herondelle, Killian, Fouyet, Sophie, Leschiera, Raphael, Le Gall-Ianotto, Christelle, Philippe, Reginald, Buscaglia, Paul, Mignen, Olivier, Lewis, Richard, Michel, Laurence, Devergne, C., Kerspern, H., Poizeau, F., Eveillard, J.R., Carré, J.L., Weisshaar, E., Evers, A.W.M., Huet, F., Ständer, S., Reich, A., Berardesca, E., Serra‐Baldrich, E., Wallengren, J., Linder, D., Fluhr, J.W., Szepietowski, J.C., Maibach, H., Honari, Golara, Takamori, Kenji, Richters, Renée, Barnetche, T., Roudot, A.‐C., Ficheux, A.‐S., Le Calloch, Ronan, Couturier, Marie‐Anne, Chauveau, Aurélie, Lippert, Eric, Carré, Jean‐Luc, Ianotto, Jean‐Christophe, Bataille, Adeline, Genin, Emmanuelle, L'Herondelle, Killian, Legoux, Nelig, Buhé, Virginie, Sakka, Mehdi, Kerfant, Nathalie, Carré, Jean-Luc, Lefeuvre, Luc, Université de Brest (UBO), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), and Laboratoire sur les interactions Epithéliums Neurones (LIEN)

Subjects
0301 basic medicine, Keratinocytes, ORAI1 Protein, [SDV]Life Sciences [q-bio], Primary Cell Culture, TRPV Cation Channels, Inflammation, Dermatitis, Dermatology, Biochemistry, Receptors, G-Protein-Coupled, 03 medical and health sciences, chemistry.chemical_compound, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], medicine, Humans, Inositol 1,4,5-Trisphosphate Receptors, Receptor, PAR-2, Calcium Signaling, RNA, Small Interfering, Molecular Biology, ComputingMilieux_MISCELLANEOUS, Calcium signaling, Phospholipase C, ORAI1, NF-κB, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Cell Differentiation, Cell Biology, Inositol trisphosphate receptor, Cell biology, 030104 developmental biology, medicine.anatomical_structure, chemistry, Tumor necrosis factor alpha, medicine.symptom, Inflammation Mediators, Keratinocyte, Oligopeptides, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

PAR2 activation in basal keratinocytes stimulates inflammation via the Ca2+-dependent production of mediators such as IL-1β, TNF-α, and TSLP. In this study, we investigated PAR2 calcium signaling and the consequent production of inflammatory mediators in differentiated human primary keratinocytes (DhPKs). Stimulation with the PAR2-activating peptide SLIGKV promoted Ca2+ store depletion in both undifferentiated human primary keratinocytes and DhPKs. SLIGKV-evoked Ca2+ store depletion did not trigger the store-operated Ca2+ entry (i.e., SOCE) through ORAI1 in DhPKs compared with undifferentiated human primary keratinocytes. The inhibition of phospholipase C and the concomitant inhibition of TRPV1 and inositol triphosphate receptor in DhPKs abrogated the SLIGKV-evoked Ca2+ store depletion; NF-κB activity; and the production of inflammatory mediators such as IL-1β, TNF-α, and TSLP. Taken together, these results indicate a key role for both InsP3R and TRPV1 in Ca2+ internal stores in the PAR2-evoked Ca2+ release and consequent skin inflammation in DhPKs. These findings may provide clues to understanding the pathological role of DhPKs in skin disorders in which PAR2 is known to be involved, such as atopic dermatitis, Netherton syndrome, and psoriasis.

Published
2017

50. Isotretinoin and risk factors for suicide attempt: a population‐based comprehensive case series and nested case–control study using 2010–2014 French Health Insurance Data.

Author

Droitcourt, C., Poizeau, F., Kerbrat, S., Balusson, F., Drezen, E., Happe, A., Travers, D., Oger, E., and Dupuy, A.

Subjects
*SUICIDE risk factors, *SUICIDAL behavior, *HEALTH insurance, *ISOTRETINOIN, *CASE-control method
Abstract

Background: Although the causal role of isotretinoin in suicidal behaviour is controversial, suicide attempts (SA) do occur among patients taking isotretinoin. Objectives: To describe patient profiles and the management of isotretinoin among patients who committed or attempted suicide under treatment. To assess the risk factors for SA under isotretinoin. Methods: We performed a comprehensive case series of suicides and SAs under isotretinoin, and a case–control study, using Nationwide French Health Insurance database. The main analysis compared cases (subjects with a SA during a course of isotretinoin) to controls, individually matched for age, gender and rank of the current course; controls were to be exposed to isotretinoin at the index date (date of SA for the corresponding cases). The patients' psychiatric history at isotretinoin initiation was studied. In a secondary analysis, patients who continued their isotretinoin treatment after their SA were compared to patients who discontinued it. Results: In all, 328 018 subjects started a course of isotretinoin between 1 January 2010 and 31 December 2014 and 184 patients were hospitalized for a SA; half of them had a psychiatric history at initiation. In the multivariate analysis, psychiatric history and history of anxiety alone were risk factors for SA [Odds ratio (OR), 18.21; 95% confidence interval (CI), 9.96–33.30 and 4.78; 95% CI, 2.44–9.33, respectively]. Among 176 cases of SA with sufficient follow‐up, 103 (58.5%) carried on with their treatment after their SA. Treatment initiation by a dermatologist was inversely associated with the continuation of the treatment after a SA (OR, 0.38; 95% CI, 0.18–0.80). Conclusions: Suicide attempts under isotretinoin are rare events, and our results suggest that most of the patients concerned have a risk‐prone profile detectable at the time of treatment initiation. The risk–benefit ratio of continuing isotretinoin after a SA warrants further careful evaluation. Linked Commentary: U. Gieler et al. J Eur Acad Dermatol Venereol 2020; 34: 1131–1133. https://doi.org/10.1111/jdv.16489. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results